School of Medicine
Showing 111-117 of 117 Results
Assistant Professor of Medicine (Infectious Diseases) and of Microbiology and Immunology
Current Research and Scholarly Interests Studies in our lab are aimed at defining mechanisms in human immunity and disease. We are particularly interested the hypothesis that IgG repertoire diversity is a central driver of heterogeneity in human immune functioning and susceptibility to infectious diseases. Our work is defining how diversity that exists in the IgG Fc domain repertoire among people, which we define by serum IgG subclass and Fc glycoform distributions, impacts immune processes such as vaccine responses and susceptibility to antibody-dependent enhancement of dengue disease (Wang TT, Cell. 2015 and Wang TT, Science. 2017). IgG subclass and Fc glycoform distributions are key regulators of immunity because these determine the structure of Fc domains within immune complexes that form during vaccination or infection. Fc structure, in turn, determines the affinity of immune complexes for various Fc receptors on effector cells. Thus, we are studying how the Fc domain repertoire of an individual impacts the quality of effector cell responses that can be recruited during immune activation and how selectivity of effector responses contributes to immunity and disease.
We are particularly interested in training students and postdocs who will go on to be independent investigators in mechanistic studies relevant to human disease.
Current clinical studies:
An Open Label Study of IgG Fc Glycan Composition in Human Immunity
Principal Investigator: Taia T. Wang, MD, PhD
Professor of Medicine (Infectious Diseases) at the Stanford University Medical Center, Emeritus
Current Research and Scholarly Interests Dr. Zolopa’s research applies a variety of clinical epidemiologic methods in an effort to optimize antiretroviral therapy and understand the impact of drug resistance on response to ARV. Areas of focus include the clinical application of resistance testing in optimizing antiretroviral therapy, clinical cohorts, trials of antiretroviral therapies and population-based epidemiologic evaluation of HIV resistance and efficacy of ARV therapy. More recently studies focused on premature aging in HIV.